| P2093 | author name string | W McNeely | |
| | P Benfield | |
| P2860 | cites work | Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study | Q71937606 |
| | The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia | Q72797825 |
| | Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group | Q74648679 |
| | Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity | Q28302803 |
| | Options for the management of obesity | Q33560645 |
| | Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers | Q34379128 |
| | Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin) | Q36731331 |
| | Combined drug treatment of obesity | Q41026192 |
| | Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin | Q41785787 |
| | Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake | Q43201554 |
| | Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. | Q51578191 |
| | The Influence of Orlistat on the Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Volunteers | Q51589056 |
| | Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. | Q51596437 |
| | Influence of dietary composition on the inhibition of fat absorption by orlistat. | Q54024643 |
| | Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin | Q67926347 |
| | Guidelines for the approval and use of drugs to treat obesity. A position paper of The North American Association for the Study of Obesity | Q70786278 |
| | The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers | Q70789848 |
| | Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects | Q71128936 |
| | Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers | Q71317116 |
| | Lack of interaction between orlistat and oral contraceptives | Q71611325 |
| | The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers | Q71622341 |
| | The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers | Q71622346 |
| | The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers | Q71622351 |
| | The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers | Q71643245 |
| | Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers | Q71703563 |
| | Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity | Q71899836 |
| P433 | issue | 2 | |
| P304 | page(s) | 241-9; discussion 250 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Orlistat | |
| P478 | volume | 56 | |